LONDON-- Merrion Pharmaceuticals PLC (3MP.DB) said Thursday that drug group Novo Nordisk A/S (NVO) expects to use Merrion's drug delivery technology GIPET in a trial for an insulin tablet.

-Merrion shares unchanged at 10 cents valuing the company at EUR8.3 million.

-Write to Rory Gallivan at rory.gallivan@wsj.com; Twitter: @RoryGallivan

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

Novo Nordisk (NYSE:NVO)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Novo Nordisk Charts.
Novo Nordisk (NYSE:NVO)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Novo Nordisk Charts.